CTOs on the Move

Presbyterian Medical Services

www.pmsnm.org

 
Presbyterian Medical Services (PMS) is the successor to the United Presbyterian Churchs Medical Mission work in the Southwest which began in 1901. In 1969, an independent PMS was formed as a New Mexico non-profit corporation to ensure continuation of...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pmsnm.org
  • 1422, Paseo De Peralta
    Santa Fe, NM USA 87501
  • Phone: 800.477.7633

Executives

Name Title Contact Details

Similar Companies

CompleGen

CompleGen is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amarillo Biosciences

Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quartesian

Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.

Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.